S16: Endolysosomal and lipid metabolism dysfunction in Parkinson’s - from dysfunction to therapeutics

S16: Endolysosomal and lipid metabolism dysfunction in Parkinson’s - from dysfunction to therapeutics

Hall 1
Sponsored Symposium

Information

Convened by Parkinson's UK

Co-Chair: Dr Esther Sammler

Co-Chair: Professor Tony Shapira

  • Dr Emil Gustavsson - Understanding transcript diversity and its impact on endolysosomal function in Parkinson’s Disease
  • Dr Esther Sammler - Impact of LRRK2 gene mutations on endolysosomal function
  • Professor Tony Shapira - Therapeutic approaches targeting the lysosomal enzyme glucocerebrosidase
  • Dr Saranna Fanning - Lipid metabolism as a therapeutic target for Parkinson’s
Theme
Ageing & neurodegeneration
Parkinson's UKStand 25We’re Parkinson’s UK. The charity that’s here to support every Parkinson’s journey, every step of the way. We don’t wait for change, we make it happen. Campaigning for better health and care. Funding research into groundbreaking new treatments. Running life-changing support services. We are currently funding over £13m towards 39 research grants. And through our drug discovery programme, the Parkinson’s Virtual Biotech, we've committed £30m towards new drug discovery and development projects for Parkinson’s. The charity uses insight from people with the condition to shape and prioritise its work, as well as improving the experiences of taking part in research. We will be sharing information about the ways we can support your research from funding opportunities to guidance and facilitation of patient and public involvement. Come and chat to us!

Registered attendees

Alex Cammack
Alex Cammack
Research FellowUCL
AN
Aline Nixon
clinical fellowUniversity of Birmingham
Antonio Fusciardi
Antonio Fusciardi
PhD studentUniversity of Exeter